Glioblastoma Pipeline Appears Promising With 200+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment
Stay ahead with the latest insights! Download DelveInsight's comprehensive Glioblastoma Pipeline Report to explore emerging therapies, key Glioblastoma Companies, and future Glioblastoma treatment landscapes @ Glioblastoma Pipeline Outlook Report
Key Takeaways from the Glioblastoma Pipeline Report
In July 2025, NovoCure GmbH announced a study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
DelveInsight's Glioblastoma pipeline report depicts a robust space with 200+ active players working to develop 220+ pipeline therapies for Glioblastoma treatment.
The leading Glioblastoma Companies such as Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals and others.
Promising Glioblastoma Pipeline Therapies such as Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.
Stay informed about the cutting-edge advancements in Glioblastoma treatments. Download for updates and be a part of the revolution in Oncology Care @ Glioblastoma Clinical Trials Assessment
Glioblastoma Emerging Drugs Profile
BMX-001: BioMimetix
BMX-001 is a metalloporphyrin, a novel class of redox-active, small molecule. The active center is designed to mimic the center of superoxide dismutase. The primary mechanism of action is modulation of cellular signaling pathways. BMX-001 inhibits both NFkB and HIF-1a. By inhibiting these pro-survival and pro-angiogenic transcription factors, BMX-001 augments tumor killing by radiation therapy and inhibits tumor regrowth. The inhibition of NFkB blocks major components of the inflammatory cascade which simultaneously results in protection of normal tissue from radiation induced injury. BMX-001 is also being developed in head and neck cancer, anal cancer, and rectal cancer. Currently, the drug is in the Phase III stage of its development for the treatment of glioblastoma.
Enzastaurin: Denovo BioPharma
DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world's first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive. The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM).
MDNA55: Medicenna Therapeutics, Inc.
MDNA55 is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A.
Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected.
When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. The drug is currently under Phase II of development.
MN-166: MediciNova
MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses the pro-inflammatory cytokines IL-1ß, TNF-a, and IL-6 and might up-regulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. While considered a New Molecular Entity, or NME, in the United States and Europe, it involves the redirection of an approved drug, ibudilast, which was first approved in Japan more than 20 years ago. Ibudilast has been prescribed to over 3.2 million patients and has a good post-marketing safety profile. Currently, the drug is in Phase II trial for the treatment of Glioblastoma.
TNG456: Tango Therapeutics, Inc.
TNG456 is an experimental targeted therapy developed to address the aggressive nature of glioblastoma, one of the most treatment-resistant brain tumors. Designed to inhibit key molecular pathways involved in tumor proliferation and immune evasion, TNG456 aims to enhance both direct tumor suppression and immune system activation. Preclinical data suggest potential synergy when used alongside standard-of-care therapies like radiotherapy or temozolomide. Its mechanism may involve disrupting tumor metabolism or modulating the tumor microenvironment. TNG456 represents a promising candidate in the evolving landscape of glioblastoma therapeutics, currently under investigation for efficacy and safety. The drug is currently in Phase I/II stage of its development for the treatment of glioblastoma.
The Glioblastoma Pipeline Report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
Glioblastoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.
Learn more about Glioblastoma Drugs opportunities in our groundbreaking Glioblastoma research and development projects @ Glioblastoma Unmet Needs
Glioblastoma Companies
Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals and others.
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Glioblastoma Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Discover the latest advancements in Glioblastoma treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Glioblastoma Market Drivers and Barriers, and Future Perspectives
Scope of the Glioblastoma Pipeline Report
Coverage- Global
Glioblastoma Companies- Denovo Biopharma, AstraZeneca, Pfizer, Chimerix, Bristol-Myers Squibb, Orbus Therapeutics, Northwest Biotherapeutics, Day One Biopharmaceuticals, AiVita Biomedical, Ascletis Pharma Inc., Bristol Myers Squibb, Kazia Therapeutics, HebaBiz Biotech, Biohaven Pharmaceuticals, Vigeo Therapeutics, Hoffman-La-Roche, TVAX Biomedical, Laminar Pharmaceuticals, Kintara Therapeutics, Medicenna Therapeutics, Symphogen A/S, MimiVax, Incyte Corporation, Istari Oncology, Immunomic Therapeutics, Celgene, Sanofi, Merck Sharp & Dohme LLC, Oblato, Inc., GlaxoSmithKline, NuvOx Pharma, Epitopoietic Research Corporation, AnHeart Therapeutics, DNAtrix, Arog Pharmaceuticals, CANbridge Pharmaceuticals, Jiangsu Hengrui Medicine, BPGbio, Inc., BioMimetix, CNS Pharmaceuticals and others.
Glioblastoma Pipeline Therapies- Axumin, Intravenous Solution, PolyMVA, MDNA55, Erlotinib HCl (OSI-774), BPM31510, Temozolomide (TMZ), and others.
Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Glioblastoma Pipeline on our website @ Glioblastoma Emerging Drugs and Companies
Table of Contents
Introduction
Executive Summary
Glioblastoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Glioblastoma– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Enzastaurin: Denovo BioPharma
Mid Stage Products (Phase II)
MDNA55: Medicenna Therapeutics, Inc.
Early Stage Products (Phase I/II)
TNG456: Tango Therapeutics, Inc.
Preclinical and Discovery Stage Products
RGN6024: Reglagene, Inc.
Inactive Products
Glioblastoma Key Companies
Glioblastoma Key Products
Glioblastoma- Unmet Needs
Glioblastoma- Market Drivers and Barriers
Glioblastoma- Future Perspectives and Conclusion
Glioblastoma Analyst Views
Glioblastoma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
21 minutes ago
- Globe and Mail
Dollar General vs. Dollar Tree: Which Discount Stock Wins the Value Game?
Key Points Dollar General struggled with macro headwinds over the past few years. Dollar Tree's divestment of Family Dollar could represent a fresh start. The pricier stock could actually be the better value. 10 stocks we like better than Dollar General › Dollar General (NYSE: DG) and Dollar Tree (NASDAQ: DLTR), the two largest dollar stores in America, both survived the retail apocalypse which wiped out many other retailers over the past decade. They kept opening new stores even as other retailers pulled back, and they countered Amazon and Walmart by selling cheaper products. That resilience made them reliable recession-resistant investments. But over the past three years, Dollar General's stock plunged more than 50% as Dollar Tree's stock dropped over 30%. Let's see why these two stocks sank -- and if either one is a better value play right now. The differences between Dollar General and Dollar Tree Dollar General mainly opens its stores in rural areas which haven't been saturated by superstores. It doesn't actually sell everything for a dollar, but it tries to sell its products at much lower prices than its competitors. It generates most of its revenue in the U.S., but it expanded into Mexico with its Mi Súper Dollar General stores in 2022. From fiscal 2021 and fiscal 2024 (which ended Jan. 31, 2025), Dollar General's number of year-end stores increased from 18,130 to 20,594. For fiscal 2025, it plans to open approximately 575 new stores in the U.S. and up to 15 new stores in Mexico. Dollar Tree focuses on urban and suburban markets, and it tries to wedge its stores between lower income neighborhoods and superstores like Walmart. It originally sold all of its products for $1, but it raised its prices over the past four years to counter inflation and sell a broader range of products. It acquired its chief competitor Family Dollar in 2015, but it finally sold the struggling banner after a decade of sluggish sales this year. From fiscal 2021 to fiscal 2024 (which ended Feb. 1, 2025), Dollar Tree's number of year-end stores (including Family Dollar) grew from 15,115 to 16,774. But in fiscal 2025, its store count will decline as it divests its Family Dollar stores. At the end of the first quarter of 2025, its Dollar Tree segment operated 9,016 stores. What challenges do the dollar stores face? Dollar General and Dollar Tree both grew their same-store sales over the past three years. Data source: Company earnings reports. *Excluding Family Dollar. Dollar General's same-store sales slowed in fiscal 2023 as it grappled with inflationary headwinds for consumer spending (especially among lower income consumers), theft and inventory shrinkage issues, and cost-cutting measures, which caused operational challenges. But in fiscal 2024, its growth accelerated again as it closed some weaker stores, prioritized operational improvements over immediate cost-cutting strategies, and opened more Popshelf concept stores to sell a broader range of higher-margin, non-essential goods. For fiscal 2025, it expects its same-store sales to rise 1.5% to 2.5% as it continues to open more Popshelf stores, adds gas stations to more of its rural Dollar General stores, remodels its older locations, and continues to open new stores in more promising markets. It expects its diluted EPS, which plunged 32% in fiscal 2024, to rise 2% to 14% in fiscal 2025. Analysts expect its EPS to grow 12% for the year, even as the unpredictable tariffs squeeze its near-term margins. Dollar Tree's same-store sales growth decelerated in fiscal 2023 and 2024 as it grappled with inflation, weak consumer spending, bloated inventories, and theft. Its decision to broaden its price range alienated some of its customers, and its "combo strategy" of merging some of its Dollar Tree and Family Dollar banners didn't halt that slowdown. But for fiscal 2025, Dollar Tree sees its same-store sales rising 3% to 5%. It expects that acceleration to be driven by its ongoing conversion of its stores to its newer multi-price "3.0 format" (with $1.25-$7.00 tiers) to attract higher income customers. The divestment of Family Dollar should also free up more cash to strengthen its main banner. Dollar Tree expects adjusted EPS from continuing operations, which dipped 12% in fiscal 2024, to rise 1% to 11% in fiscal 2025. Analysts expect its adjusted EPS to grow 6%. Which dollar store stock is the better value right now? Dollar General trades at 20 times forward earnings and pays a forward dividend yield of 2.2%. Dollar Tree trades at 21 times forward earnings but doesn't pay a dividend. Dollar General might be the cheaper stock, but I think Dollar Tree's divestment of Family Dollar, its stronger same-store sales growth, and it's clearer plans for broadening its reach among higher-income consumers make it the more compelling investment. Dollar General's focus on rural areas limits its ability to attract more affluent customers, while its expansion of Popshelf could run into a lot of competition from similar retailers like Five Below. Should you invest $1,000 in Dollar General right now? Before you buy stock in Dollar General, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dollar General wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025
Globe and Mail
36 minutes ago
- Globe and Mail
How Databricks Is Quietly Becoming One of the Most Powerful AI Stocks Yet to Go Public
Key Points Databricks has emerged as a competitive threat to Snowflake. A $15 billion fundraising round earlier this year confirms the excitement around this company. According to the CFO, revenue was on track to rise 50% yearly through July. 10 stocks we like better than Snowflake › Databricks has attracted increasing attention in recent months. Although it is currently a privately held company, it raised a considerable amount of money earlier this year and reported an annualized revenue projection despite private companies not being required to disclose such information. It also announced global expansions and additional hiring that will heavily focus on recruiting talent in the artificial intelligence (AI) field. Not surprisingly, such revelations have led to speculation on when Databricks might launch an IPO. While it has not publicly announced such an intention, the company has arguably become the most prominent AI company not trading on the market. Here's why. Databricks described Databricks is a data cloud platform and stands out by utilizing a data lakehouse platform. This combines a data warehousing platform with a data lake, which stores data in a raw format. Through the platform, users can store structured, semi-structured, and unstructured data in the cloud. Databricks also enables its clients to secure, manage, structure, and apply data for use in analytics and performing machine learning workloads. It is also a more appealing alternative to storing data in silos, which makes data governance and protecting its integrity difficult. Databricks also accomplishes many of its tasks through the Mosaic AI platform. It helps developers design generative AI applications to find relevant documents and data that provide context for large language models, thereby increasing the accuracy of responses. This leads to inevitable comparisons with its peers. One is MongoDB, whose nonrelational database has grown in popularity. Still, the competitor grabbing the most attention appears to be Snowflake (NYSE: SNOW). Snowflake is a competing data cloud company that drew investor attention when it received backing from Warren Buffett's Berkshire Hathaway before its September 2020 IPO. Will Databricks go public? Snowflake's history as a public company may also be a reason Databricks might consider an IPO. Although Snowflake sells for far below its 2021 high, it has grown substantially from the IPO price of $120 per share in 2020. Admittedly, Snowflake was not immune to selling during the 2022 bear market, and Berkshire later exited its position. Nonetheless, it has consistently commanded a valuation premium, and with a price-to-sales (P/S) ratio of 19, Snowflake stock remains relatively expensive. Moreover, Databricks' recent fundraising round and financial revelations may also indicate both its value as a start-up and its intention to go public. Early this year, the company raised $15.3 billion in equity financing, which gave it a presumed valuation of $62 billion, not far below Snowflake's current market cap of $71 billion. As mentioned, Databricks has also increasingly made voluntary financial disclosures. Last month at the Data and AI Summit, CFO Dave Conte stated that he expected Databricks to generate $3.7 billion in annualized revenue through July, representing a 50% yearly increase. Such news affirms the company's success, making it easier to draw attention if it later announces a plan to go public. Databricks' role in the AI space moving forward Although Databricks remains a private company, its successes make it one AI company investors need to watch. Databricks' role as a data cloud company makes it a prominent player in the AI space, and the competitive threat it poses to rival Snowflake should be closely watched by Snowflake shareholders and tech investors in general. Also, the company's $15 billion fundraising haul last year shows that private investors are already on board. Additionally, the success of Snowflake's IPO and its premium valuation could bode well for Databricks, should it go public. Considering Databricks' 50% revenue growth and the continued investor focus on AI, the company is likely to hold the attention of investors, regardless of whether it remains private or launches what would likely be a highly anticipated IPO. Should you invest $1,000 in Snowflake right now? Before you buy stock in Snowflake, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Snowflake wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025
Globe and Mail
42 minutes ago
- Globe and Mail
Bull of the Day: Amazon (AMZN)
Amazon AMZN stock has seen a sharp rebound in the last three months, surging more than +20% to help lead the unprecedented recovery among the broader indexes. That said, with tariff uncertainty starting to become somewhat benign in regard to affecting the stock market, Amazon stock looks poised to keep soaring ahead of its Q2 results on Thursday, July 31. Keeping this in mind, let's take a look at Amazon's Q2 growth expectations and a few catalysts that could keep lifting AMZN shares from here. Amazon's Q2 Expectations & The Zacks ESP As a brief preview, Amazon's Q2 sales are thought to have increased 9% to $162.28 billion compared to $147.98 billion a year ago. On the bottom line, Amazon's Q2 earnings are expected to be up 8% to $1.33 per share from EPS of $1.23 in the prior period. Notably, Amazon has exceeded the Zacks EPS Consensus for 10 consecutive quarters with a very impressive average earnings surprise of 20.68% in its last four quarterly reports. More intriguing, the Zacks ESP (Expected Surprise Prediction) indicates Amazon could keep this compelling streak of beating earnings expectations going with the Most Accurate and recent estimate among Wall Street analysts having Q2 EPS pegged at $1.42 and 7% above the underlying Zacks Consensus (Current Qtr below). Amazon 'Prime Week' Takes Off As reason to believe Amazon could offer very favorable guidance for Q3, the e-commerce giant's Prime Day event has been stretched to four days (July 8-11) and recently shattered previous records. Being Amazon's largest sales event on record, U.S. online sales for what could now be deemed as "Prime Week" are thought to have hit $24.1 billion. It's noteworthy that AI-driven advertising was a large contributer. To that point, Adobe Analytics reported a 3,300% surge in AI-driven traffic during "Prime Week" after analyzing over a trillion visits to retail sites. This mind-blowing spike refers to traffic generated from generative AI tools like Amazon's AI-powered shopping assistant 'Rufus' and its revamped next-generation voice assistant 'Alexa+'. Key Points of Amazon's AI Expansion In the grand scheme of things, Amazon is focused on using AI to supercharge its cloud division, Amazon Web Services (AWS), which is still the largest cloud service ahead of Microsoft's MSFT Azure and Alphabet's GOOGL Google Cloud. 1. Nova models: Amazon's proprietary generative and agentic AI models, integrated across Alexa+, shopping (Rufus), and AWS services. 2. Custom AI chips: Continued development of its own custom AI chips, including the Trainium 2 and the upcoming Trainium 3, designed to outperform traditional GPUs in cost and efficiency. 3. Amazon Bedrock: A marketplace for foundational large language models (LLMs) from leaders like Anthropic, Meta Platforms META, Mistral, and others, allowing developers to build AI apps without managing infrastructure. 4. Data Center Buildouts & Sustainability Push: New AI-ready data centers in Pennsylvania and North Carolina that are collocated with nuclear power facilities to complement investments in small modular reactors (SMRs) that power AI workloads with carbon-free electricity. Amazon's EPS Growth & Revisions Correlating with the rebound in Amazon stock, EPS revisions have continued to trend higher in the last 60 days for fiscal 2025 and FY26. Amazon's annual earnings are now expected to increase 13% this year and are projected to spike another 16% in FY26 to $7.28 per share. Image Source: Zacks Investment Research Furthermore, following the pandemic, FY26 EPS projections would reflect 248% growth with Amazon's post-split adjusted earnings being the equivalent of $2.09 a share in 2020. (Amazon did a 20-1 Stock Split in June of 2022). Conclusion & Final Thoughts As a reminder that Amazon's stock previously traded over $2000 a share before its most recent stock split, now appears to be an ideal time to buy AMZN before it gets more expensive. At the moment, the Average Zacks Price Target for Amazon stock is $254, suggesting 10% upside from current levels. However, it would be no surprise if this consensus price target is eventually lifted toward $300 or higher, considering the tech giant's businesses are starting to be streamlined by AI. Higher. Faster. Sooner. Buy These Stocks Now A small number of stocks are primed for a breakout, and you have a chance to get in before they take off. At any given time, there are only 220 Zacks Rank #1 Strong Buys. On average, this list more than doubles the S&P 500. We've combed through the latest Strong Buys and selected 7 compelling companies likely to jump sooner and climb higher than any other stock you could buy this month. You'll learn everything you need to know about these exciting trades in our brand-new Special Report, 7 Best Stocks for the Next 30 Days. Download the report free now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report Meta Platforms, Inc. (META): Free Stock Analysis Report
